GlassScriptPhysician profile
Hanh Cline
NPI 1538307970
$4,522.94
in general payments reported to CMS, 2019-2025
32 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $609 · 2023: $586 · 2024: $1,341 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.98 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.56 | 2021-2025 | |
| Pfizer INC. | $456.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $376.29 | 2024 | Tezspire, Airsupra, Breztri |
| Astellas Pharma US INC | $354.84 | 2022-2023 | Veozah, Myrbetriq |
| Medtronic, INC. | $340.30 | 2023-2025 | Venaseal |
| Zynex Medical, INC. | $262.23 | 2025 | Nexwave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.02 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $234.21 | 2023-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $177.84 | 2024-2025 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $175.12 | 2024-2025 | Rexulti |
| Therapeuticsmd, INC. | $161.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.19 | 2022-2025 | |
| Amgen INC. | $137.47 | 2024-2025 | Tavneos, Repatha, Otezla |
| Exact Sciences Corporation | $125.28 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $109.31 | 2025 | Epclusa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $95.96 | 2024 | Valtoco |
| Abbott Laboratories | $92.19 | 2023-2024 | Freestyle Libre 3 |
| Intuitive Surgical, INC. | $90.35 | 2025 | |
| Glaxosmithkline, LLC. | $70.06 | 2024-2025 | Arexvy, Shingrix, Penmenvy |
| Daiichi Sankyo INC. | $65.06 | 2022-2023 | Injectafer |
| Dexcom, INC. | $45.88 | 2025 | Dexcom G6 Transmitter |
| Coloplast Corp | $41.49 | 2023 | Restorelle |
| Organon LLC | $29.26 | 2024 | |
| Urovant Sciences INC | $27.70 | 2022 | |
| 180 Medical, INC. | $27.30 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.79 | 2025 | |
| Lilly USA, LLC | $24.85 | 2024 | Zepbound |
| Medline Industries LP | $21.57 | 2022 | |
| Edwards Lifesciences Corporation | $19.65 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $19.07 | 2022 | |
| Myovant Sciences INC. | $18.67 | 2021 | |
| Aimmune Therapeutics, INC. | $17.46 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanh Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.